Goldman Sachs’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Goldman Sachs’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-37,400	Closed	-$1.47M	–	6067
2023 Q2	$1.47M	Buy	+37,400	New	+$1.32M	﹤0.01%	4084
2022 Q4	–	Sell	-75,000	Closed	-$1.35M	–	6396
2022 Q3	$1.35M	Buy	+75,000	New	+$984K	﹤0.01%	4317
2017 Q1	–	Sell	-195,400	Closed	-$944K	–	7073
2016 Q4	$944K	Buy	195,400 +112,600	+136%	+$3.34M	﹤0.01%	4509
2016 Q3	$3.82M	Buy	82,800 +50,300	+155%	+$2.84M	﹤0.01%	3275
2016 Q2	$1.66M	Sell	32,500 -45,300	-58%	-$2.25M	﹤0.01%	3768
2016 Q1	$3.29M	Buy	77,800 +27,800	+56%	+$1.42M	﹤0.01%	3056
2015 Q4	$3.93M	Hold	50,000	–	–	﹤0.01%	3057
2015 Q3	$2.03M	Buy	+50,000	New	+$2.65M	﹤0.01%	3784

Goldman Sachs's ISEE Position: Q3 2023 in Review

Goldman Sachs sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 4,222,280 shares — an estimated $166M sold.

Goldman Sachs first reported a position in ISEE in Q4 2013 and held it in 37 quarters. The position peaked at $166M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Goldman Sachs reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Goldman Sachs sold 4,222,280 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $166M.
Goldman Sachs first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 37 quarters.
Goldman Sachs's IVERIC bio, Inc. Common Stock position peaked at $166M in Q2 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.